New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
NCT ID NCT03697408
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, itacitinib and everolimus, can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatments. The trial is open to adults with measurable disease and aims to see how well the combination works in shrinking or eliminating tumors. Participants receive both drugs and are monitored for safety and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
itacitinib and everolimus
What this could lead to
If successful, this drug combination could offer a new treatment option for people with Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States